Qualcomm Swings to Loss on Settlement; Raises Guidance

Telecom company Qualcomm ( QCOM), shares spiked Monday morning, after the company reported first-quarter earnings that included a big legal settlement with its arch rival Broadcom ( BRCM). Qualcomm said that after a more than four-year legal battle over patent infringement issues with Broadcom, the two sides finally reached an agreement late Sunday night that requires Qualcomm to pay $891 million over the next four years.

Because of this settlement, Qualcomm posted a fiscal first-quarter net loss of $289 million, or 18 cents per share, compared with a profit of $766 million, or 47 cents per share, in the year-ago quarter. Excluding special items, the company would have seen profits of 3 cents per share.

On average, Wall Street analysts expected profit of 40 cents per share.

Revenue fell to $2.46 billion from $2.6 billion last year, but still beat analyst estimates for $2.35 billion.

The company said that global demand for new wireless phones remained strong, citing China as a high-growth area.

Qualcomm raised its 2009 full-year revenue estimates to a range of $9.85 billion to $10.25 billion, up from an earlier range of $9.3 billion to $9.8 billion.

Qualcomm shares rose $2.36, or +5.6%, in late morning trading Monday.

We removed shares of QCOM from our "Recommended" list back on Sept. 25, when the stock traded at $46.54. The company will know have a dividend yield of 1.64%, based on Friday's closing stock price of $32.79.

The stock has technical support in the $33-$37 price area. If the shares can firm up, we see overhead resistance around the $45-$48 price levels. We just put the stock on our "upgrade" watchlist and will keep subscribers posted as to any further ratings changes.

If you liked this article you might like

Facebook and Snap Have One Issue That Will Have to Be Solved: Peter Bonfield

10 Biggest Takeaways from Apple's iPhone X Event

Google Pixel 2 Debuting October 4, FYI Apple

The iPhone X Highlights This Overlooked Strength of Apple's

Arconic, Idexx Laboratories, AbbVie: 'Mad Money' Lightning Round